Phase 4
Completed N=6
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
Parkinson's Disease · Deep Brain Stimulation Surgery
Source: ClinicalTrials.gov NCT01721460 ↗
Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Nov 2017
Primary outcomePrimary: Change in Average Population Spiking Activity — 42.8 Percent change
◆ Published Evidence
Emerging
7citations · ~2 / year
Dexmedetomidine depresses neuronal activity in the subthalamic nucleus during deep brain stimulation electrode implantation surgery.
Summary
The purpose of this research study is to find out whether dexmedetomidine changes brain cell activity in the subthalamic nucleus (STN).
Linked Publications
-
Dexmedetomidine depresses neuronal activity in the subthalamic nucleus during deep brain stimulation electrode implantation surgery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Average Population Spiking Activity |
42.8 | — |
| SECONDARY Change in Average Firing Pattern in the STN |
39.9 | — |
| SECONDARY Time to Recovery |
16 | — |
| SECONDARY Portion of Participants With Timely Return of the Neuronal Activity to Baseline |
2 | — |
Eligibility Criteria
Inclusion Criteria
- Patients scheduled to undergo bilateral STN electrode implantation surgery with Micro-electrode recording for the treatment of Parkinson's disease.
Exclusion Criteria
- Hypersensitivity to dexmedetomidine
- Bradycardia: Sinus rhythm slower than 50 bpm
- Known or suspected obstructive sleep apnea
- Suspected difficult intubation
- Pregnancy
- Under 18 years of age or over 85 years of age
- Cognitive disability impairing understanding the experiment or signing the informed consent form
Data sourced from ClinicalTrials.gov (NCT01721460) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.